Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
The patient took all Vivotif doses within the series with food; Case reference number US-BN-2025-000860 is a spontaneous case report initially received from a nurse via Communication (reference number: USBAV25-0916) on 23-Apr-2025 and concerns a female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient took with food unspecified number of doses, reported as all doses of Vivotif vaccine (batch number: unknown) at an unknown dose orally for indication protection against typhoid fever (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: This case concerned a female patient of unknown age/age group. As reported, the patient took unspecified number of doses of Vivotif vaccine (reportedly all doses) at an unknown dose orally along with food, for indication protection against typhoid fever which is considered as 'product administration error'. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Product administration error is considered as listed as per company convention. The patients' medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerned a female patient of unknown age/age group. As reported, the patient took unspecified number of doses of Vivotif vaccine (reportedly all doses) at an unknown dose orally along with food, for indication protection against typhoid fever which is considered as 'product administration error'. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Product administration error is considered as listed as per company convention. The patients' medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.